Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

Mayuko Furuta,Hiroko Tanaka,Yuichi Shiraishi,Takuro Unida,Michio Imamura,Akihiro Fujimoto,Masahi Fujita,Aya Sasaki-Oku,Kazuhiro Maejima,Kaoru Nakano,Yoshiiku Kawakami,Koji Arihiro,Hiroshi Aikata,Masaki Ueno,Shinya Hayami,Shun-Ichi Ariizumi,Masakazu Yamamoto,Kunihito Gotoh,Hideki Ohdan,Hiroki Yamaue,Satoru Miyano,Kazuaki Chayama,Hidewaki Nakagawa,Takuro Uchida
DOI: https://doi.org/10.18632/oncotarget.25308
2018-05-18
Oncotarget
Abstract:Integration of Hepatitis B virus (HBV) into the human genome can cause genetic instability, leading to selective advantages for HBV-induced liver cancer. Despite the large number of studies for HBV integration into liver cancer, little is known about the mechanism of initial HBV integration events owing to the limitations of materials and detection methods. We conducted an HBV sequence capture, followed by ultra-deep sequencing, to screen for HBV integrations in 111 liver samples from human-hepatocyte chimeric mice with HBV infection and human clinical samples containing 42 paired samples from non-tumorous and tumorous liver tissues. The HBV infection model using chimeric mice verified the efficiency of our HBV-capture analysis and demonstrated that HBV integration could occur 23 to 49 days after HBV infection via microhomology-mediated end joining and predominantly in mitochondrial DNA. Overall HBV integration sites in clinical samples were significantly enriched in regions annotated as exhibiting open chromatin, a high level of gene expression, and early replication timing in liver cells. These data indicate that HBV integration in liver tissue was biased according to chromatin accessibility, with additional selection pressures in the gene promoters of tumor samples. Moreover, an integrative analysis using paired non-tumorous and tumorous samples and HBV-related transcriptional change revealed the involvement of <i>TERT</i> and <i>MLL4</i> in clonal selection. We also found frequent and non-tumorous liver-specific HBV integrations in <i>FN1</i> and <i>HBV-FN1</i> fusion transcript. Extensive survey of HBV integrations facilitates and improves the understanding of the timing and biology of HBV integration during infection and HBV-related hepatocarcinogenesis.
What problem does this paper attempt to address?